Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 1
Submit an article Journal homepage
150
Views
38
CrossRef citations to date
0
Altmetric
Research Article

Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma

Juan José Lahuerta Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Carlos Grande Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Joan Blade Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Joaquín Martínez-López Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Javier de la Serna Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Adrian Alegre Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
José García LaraÑa Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Dolores Caballero Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Javier de la Rubia Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Julián Marı´n Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Cristina Perez-Lopez Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Anna Sureda Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Antonio Escudero Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Rafael Cabrera Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Eulogio Conde Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Juan Carlos García-Ruiz Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Katty Pérez-Equiza Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Fernado Hernandez Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Luis Palomera Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Angel León Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Pilar Giraldo Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Carlos Solano Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Joan Bargay Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
&
Jesús San Miguel Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
 show all
Pages 67-75 | Published online: 01 Jul 2009

Citations (38)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Ga-Young Song, Sung-Hoon Jung, Je-Jung Lee, Jin Seok Kim, Chang-Ki Min, Kihyun Kim, Yunsuk Choi, Hyeon-Seok Eom, Young Don Joo, Sung-Hyun Kim, Jae-Yong Kwak, Hye Jin Kang, Jae Hoon Lee, Ho Sup Lee, Yeung-Chul Mun, Joon Ho Moon, Sang Kyun Sohn, Seong Kyu Park, Yong Park, Ho-Jin Shin & Sung-Soo Yoon. (2020) Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. Leukemia & Lymphoma 61:11, pages 2714-2721.
Read now
Massimo Martino, Attilio Olivieri, Massimo Offidani, Ernesto Vigna, Tiziana Moscato, Roberta Fedele, Mauro Montanari, Giuseppe Console, Massimo Gentile, Giuseppe Messina, Giuseppe Irrera & Fortunato Morabito. (2013) Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opinion on Investigational Drugs 22:5, pages 619-634.
Read now
Pellegrino Musto & Fiorella D'Auria. (2007) Melphalan: old and new uses of a still master drug for multiple myeloma. Expert Opinion on Investigational Drugs 16:9, pages 1467-1487.
Read now
Morie A Gertz, Martha Q Lacy, Angela Dispenzieri, Suzanne R Hayman & Shaji K Kumar. (2006) High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Review of Anticancer Therapy 6:3, pages 343-360.
Read now

Articles from other publishers (34)

Mihee Kim, Je-Jung Lee, Chang-Ki Min, Ji Yun Lee, Jae-Cheol Jo, Sung-Soo Yoon, Sung-Nam Lim, Young Rok Do, Kihyun Kim, Jae Hoon Lee, Kwai Han Yoo, Sung Hwa Bae, Jun Ho Yi, Jongheon Jung, Hyeon-Seok Eom & Sung-Hoon Jung. (2023) Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015). Annals of Hematology 102:8, pages 2233-2240.
Crossref
Fei Gao, Mei-Si Lin, Jie-Shu You, Min-Yue Zhang, Long Cheng, Ke Lin, Peng Zhao & Qi-Yan Chen. (2021) Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis. Cancer Cell International 21:1.
Crossref
Songyi Park, Dong-Yeop Shin, Junshik Hong, Inho Kim, Youngil Koh, Ja Min Byun & Sung-Soo Yoon. (2021) Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma . Therapeutic Advances in Hematology 12, pages 204062072110129.
Crossref
Neeraj SainiQaiser Bashir, Denái R. MiltonGuilin Tang, Ruby DelgadoGabriela RondonUday R. Popat, Chitra M. HosingYago Nieto, Partow KebriaeiAmin M. AlousiRohtesh MehtaSamer SrourIssa F. KhouriDonna M. Weber, Sheeba K. Thomas, Hans C. Lee, Krina K. Patel, Robert Z. Orlowski, Richard E. Champlin & Muzaffar H. Qazilbash. (2020) Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Advances 4:19, pages 4834-4837.
Crossref
Qaiser Bashir, Peter F Thall, Denái R Milton, Patricia S Fox, Jitesh D Kawedia, Partow Kebriaei, Nina Shah, Krina Patel, Borje S Andersson, Yago L Nieto, Ben C Valdez, Simrit Parmar, Gabriela Rondon, Ruby Delgado, Chitra Hosing, Uday R Popat, Betul Oran, Stefan O Ciurea, Pei Lin, Donna M Weber, Sheeba K Thomas, Hans C Lee, Elisabet E Manasanch, Robert Z Orlowski, Loretta A Williams, Richard E Champlin & Muzaffar H Qazilbash. (2019) Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. The Lancet Haematology 6:5, pages e266-e275.
Crossref
Patrick Alan Hagen & Patrick Stiff. (2019) The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation 25:3, pages e98-e107.
Crossref
Moaath Mustafa Ali, Donna M. Corrigan, Lisa A. Rybicki, Melissa A. Yurch, Kelly Cherni, Hien Liu, Robert Dean, Betty Hamilton, Brad Pohlman, Steven Andresen, Matt Kalaycio, Brian J. Bolwell, Navneet S. Majhail & Ronald Sobecks. (2018) Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma. Hematology/Oncology and Stem Cell Therapy 11:4, pages 253-256.
Crossref
Sung-Hoon Jung, Je-Jung Lee, Jin Seok Kim, Chang-Ki Min, Kihyun Kim, Yunsuk Choi, Hyeon-Seok Eom, Young Don Joo, Sung-Hyun Kim, Jae-Yong Kwak, Hye Jin Kang, Jae Hoon Lee, Ho Sup Lee, Yeung-Chul Mun, Joon Ho Moon, Sang Kyun Sohn, Seong Kyu Park, Yong Park, Ho-Jin Shin & Sung-Soo Yoon. (2018) Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). Biology of Blood and Marrow Transplantation 24:5, pages 923-929.
Crossref
Ja Min ByunJayoun LeeSang-Jin ShinMinjoo KangSung-Soo YoonYoungil Koh. (2018) Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma. Blood Research 53:2, pages 105.
Crossref
Stefan K. Barta, Rishi Jain, Amithaba Mazumder, Jason Carter, Lawrence Almanzar, Roy Browne, Samira Shahnaz, Richard Elkind, David Kaminetzky, Ramakrishna Battini, Olga Derman, Noah Kornblum, Amit Verma & Ira Braunschweig. (2017) Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 17:10, pages 650-657.
Crossref
Reinhold Munker, Ali Baghian, Yordanka Koleva, Patricia Andrews, Gunita S. Matharoo, Ato E. Wright, Nakhle S. Saba, Roy S. Weiner & Hana Safah. (2017) Long-term follow-up of patients with multiple myeloma treated with total body irradiation-Melphalan conditioning. European Journal of Haematology 99:1, pages 56-59.
Crossref
Tulio E. Rodriguez, Parameswaran Hari, Patrick J. Stiff, Scott E. Smith, Danielle Sterrenberg & David H. Vesole. (2016) Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation 22:8, pages 1391-1396.
Crossref
M. Byrne, J.R. Wingard & J.S. Moreb. (2013) Continuous Infusion Cyclophosphamide and Low-Dose Total Body Irradiation Is a Safe and Effective Conditioning Regimen for Autologous Transplant in Multiple Myeloma. Transplantation Proceedings 45:9, pages 3361-3365.
Crossref
Donna ReeceKevin SongRichard LeBlancKhalid MezziAde OlujohungbeDarrell WhiteFaraz ZamanAndrew Belch. (2013) Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma. The Oncologist 18:5, pages 611-618.
Crossref
Margarita Blanes, Juan J. Lahuerta, José D. González, Paz Ribas, Carlos Solano, Adrían Alegre, Joan Bladé, Jesús F. San Miguel, Miguel A. Sanz & Javier de la Rubia. (2013) Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. Biology of Blood and Marrow Transplantation 19:1, pages 69-74.
Crossref
Giampaolo Talamo, Kevin L. Rakszawski, Witold B. Rybka, Nathan G. Dolloff, Jozef Malysz, Tamara Berno & Maurizio Zangari. (2012) Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high‐dose melphalan in patients with multiple myeloma. European Journal of Haematology 89:2, pages 145-150.
Crossref
Josien C. Regelink, Hyacintha M. van Roessel, Karin P.M. van Galen, Gert J. Ossenkoppele, Peter C. Huijgens & Sonja Zweegman. (2011) Reply to J. de la Rubia et al. Journal of Clinical Oncology 29:15, pages e450-e450.
Crossref
Kazutaka Sunami, Katsuji Shinagawa, Morio Sawamura, Akira Sakai, Yoshio Saburi, Yutaka Imamura, Ishikazu Mizuno, Shigehisa Tamaki, Tomohiko Kamimura, Hiroyuki Tsuda, Hisashi Gondo, Norihiko Hino, Chihiro Shimazaki, Akira Miyata, Fumihito Tajima, Yoshinobu Takemoto, Akiyoshi Miwa, Takaaki Chou & Mine Harada. (2009) Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma. International Journal of Hematology 90:5, pages 635-642.
Crossref
G Talamo, D F Claxton, D W Dougherty, C W Ehmann, J Sivik, J J Drabick & W Rybka. (2009) BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma. Bone Marrow Transplantation 44:3, pages 157-161.
Crossref
Enric Carreras, Laura Rosiñol, Maria José Terol, Adrián Alegre, Felipe de Arriba, José García-Laraña, José Luis Bello, Raimundo García, Angel León, Rafael Martínez, M. Jesús Peñarrubia, Concha Poderós, Paz Ribas, Josep Maria Ribera, Jesús San Miguel, Joan Bladé & Juan José Lahuerta. (2007) Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients. Biology of Blood and Marrow Transplantation 13:12, pages 1448-1454.
Crossref
Don M. BensonJr.Jr., Patrick J. Elder, Thomas S. Lin, William Blum, Sam Penza, Belinda Avalos, Edward Copelan & Sherif S. Farag. (2007) High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leukemia Research 31:8, pages 1069-1075.
Crossref
J. Vela-Ojeda, M. A. García-Ruiz-Esparza, Y. Padilla-González, D. Gómez-Almaguer, C. H. Gutiérrez-Aguirre, D. Gómez-Rangel, A. Morales-Toquero, G. J. Ruiz-Delgado, J. L. Delgado-Lamas & G. J. Ruiz-Argüelles. (2007) Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan. Annals of Hematology 86:4, pages 277-282.
Crossref
Brett T. Brinker, Edmund K. Waller, Traci Leong, Leonard T. Heffner, Jr.Istvan Redei, Amelia A. Langston & Sagar Lonial. (2006) Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 106:10, pages 2171-2180.
Crossref
Alastair Smith, Finn Wisloff & Diana Samson. (2006) Guidelines on the diagnosis and management of multiple myeloma 2005. British Journal of Haematology 132:4, pages 410-451.
Crossref
R L Comenzo, H Hassoun, T Kewalramani, V Klimek, M Dhodapkar, L Reich, J Teruya-Feldstein, M Fleisher, D Filippa & S D Nimer. (2005) Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. Leukemia 20:2, pages 345-349.
Crossref
Jean-Luc Harousseau, Philippe Moreau, Michel Attal, Thierry Facon & Hervé Avet-Loiseau. (2005) Stem-cell transplantation in multiple myeloma. Best Practice & Research Clinical Haematology 18:4, pages 603-618.
Crossref
Amir A. Toor, John Ayers, Joan Strupeck, Mala Parthasarathy, Steve Creech, Tulio Rodriguez & Patrick J. Stiff. (2004) Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. British Journal of Haematology 124:6, pages 769-776.
Crossref
Philippe Moreau & Jean-Luc Harousseau. (2004) Hematopoietic cell transplantation in multiple myeloma. Current Opinion in Organ Transplantation 9:1, pages 39-42.
Crossref
Jean-Luc Harousseau, Michel Attal & Gary J. Schiller. 2004. Biology and Management of Multiple Myeloma. Biology and Management of Multiple Myeloma 159 182 .
Laurence Catley & Kenneth Anderson. 2003. Thomas' Hematopoietic Cell Transplantation. Thomas' Hematopoietic Cell Transplantation 1262 1282 .
Theresa Hahn, John R. Wingard, Kenneth C. Anderson, William I. Bensinger, James R. Berenson, Greg Brozeit, Joseph R. Carver, Robert A. Kyle & Philip L. McCarthyJrJr. (2003) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based review. Biology of Blood and Marrow Transplantation 9:1, pages 4-37.
Crossref
Juan José Lahuerta, Carlos Grande, Joaquín Martínez-Lopez, Javier De La Serna, Rosa Toscano, María Cruz Ortiz, Santiago Larregla, Eulogio Conde, Andrés Insunza, José David Gonzalez-San Miguel, Juan Bargay, Rafael Cabrera, Juan Carlos García-Ruiz, Carmen Albó, Luis García-Alonso, Fernando Solano, Pilar Vivancos, Angel León & Jesús San Miguel. (2003) Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Ósea phase II trial. British Journal of Haematology 120:2, pages 296-303.
Crossref
Jean-Luc Harousseau & Michel Attal. (2002) The role of stem cell transplantation in multiple myeloma. Blood Reviews 16:4, pages 245-253.
Crossref
. (2002) Current Awareness in Hematological Oncology. Hematological Oncology 20:4, pages 189-196.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.